Organisation paid for research Program year 2023 Source: CMS Open Payments

CBCC Global Research, Inc.

Neither a doctor nor a teaching hospital

Research payments

$255,934

47 payments

Through program year 2023, CBCC Global Research, Inc. is reported as receiving $255,934 in research payments, across 47 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $4,850 2
2022 Research $5,312 2
2021 Research $37,987 2
2020 Research $152,624 24
2019 Research $55,160 17

Breakdown

Who paid Research payments · program years 2019–2023
  1. Merck Sharp & Dohme Corporation $241,495 35 payments
  2. Dova Pharmaceuticals $5,200 1 payment
  3. Sobi, Inc $4,850 2 payments
  4. Gilead Sciences, Inc. $4,389 9 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 $194,672 19 payments
  2. A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na , metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 $37,987 2 payments
  3. A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participants with treatment-na , metastatic nonsmall cell lung cancer NSCLC whose tumors have a tumor proportion score TPS greater than or equal to 1 LEAP-007 $5,312 2 payments
  4. Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer. $5,200 1 payment
  5. Ava-Cit-330 $4,850 2 payments
  6. A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 $3,523 12 payments
  7. A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors $1,512 1 payment
  8. A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors $745 1 payment
  9. A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors $572 1 payment
  10. A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors $452 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record